N. Yasuda, T. Inoue, T. Horizoe, K. Nagata, H. Minami, T. Kawata, Y. Hoshino, H. Harada, S. Yoshikawa, O. Asano, J. Nagaoka, M. Murakami, S. Abe, S. Kobayashi and I. Tanaka, “Functional Characterization of the Adenosine Receptor Contributing to Glycogenolysis and Gluconeogenesis in Rat Hepatocytes,” European Journal of Pharmacology, Vol. 459, No. 2-3, 2003, pp. 159-166.
http://dx.doi.org/10.1016/S0014-2999(02)02832-7

has been cited by the following article:

• TITLE: The Adenosine Receptor Agonist 5’-N-Ethylcarboxamide-Adenosine Increases Glucose 6-Phosphatase Expression and Gluconeogenesis

  AUTHORS: Koichi Matsuda, Yoko Horikawa, Yasuto Sasaki, Shigeko F. Sakata

  KEYWORDS: 5’-N-Ethylcarboxamide-Adenosine; Glucose 6-Phosphatase; Gluconeogenesis

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.1, January 8, 2014

  ABSTRACT: Intraperitoneal administration of the non-selective adenosine receptor agonist 5’-N-ethylcarboxamide-adenosine (NECA) (0.1 or 0.3 mg/kg) increased fasting serum glucose levels in mice. To clarify the mechanism responsible for this, the expression of liver glucose 6-phosphatase (G6Pase: a gluconeogenic enzyme) was analyzed, and it was found that G6Pase mRNA was increased by NECA treatment. Administration of 0.3 mg/kg NECA resulted in elevated serum glucose levels at 1 h and were further elevated at 6 h. Administration of 0.1 mg/kg NECA increased serum glucose levels at 1 h and had returned to control levels by 6 h. The increase in fasting serum glucose levels induced by NECA are thought to be caused, in part, by elevated G6Pase expression.